Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide eligibility depends on multiple clinical factors—not just weight or BMI. FDA-approved semaglutide (Wegovy for weight loss, Ozempic for type 2 diabetes) requires a BMI ≥27 with weight-related comorbidities or BMI ≥30; however, individual health history, medication interactions, and metabolic markers play equally important roles in determining candidacy.

Understanding your full clinical context—including baseline glucose metabolism, inflammatory markers, and genetic factors influencing GLP-1 receptor sensitivity—can help you and your provider make more informed decisions about semaglutide therapy. PlexusDx's precision-wellness approach integrates medical history with optional biomarker and genetic assessments to support personalized treatment planning.

Primary Medical Eligibility Criteria for Semaglutide Use

For weight loss (Wegovy), semaglutide is indicated for adults with a BMI ≥27 kg/m² and at least one weight-related condition (hypertension, type 2 diabetes, cardiovascular disease) or a BMI ≥30 kg/m² regardless of comorbidities. For type 2 diabetes management (Ozempic), prescription requires an existing diabetes diagnosis and inadequate glycemic control on current therapy.

Beyond BMI, healthcare providers assess kidney function (eGFR), liver health (AST/ALT), personal history of pancreatitis or thyroid cancer, and current medication list. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindicated. Recent bariatric surgery may also affect candidacy due to altered gastrointestinal absorption.

Baseline Biomarkers That Inform Semaglutide Assessment

Before starting semaglutide, baseline lab work provides critical context. Fasting glucose, HbA1c, lipid panel, liver and kidney function, and thyroid-stimulating hormone (TSH) establish your metabolic starting point and help identify any contraindications or dose-adjustment needs. Inflammatory markers such as high-sensitivity C-reactive protein may also reveal underlying metabolic risk.

Biomarker Why It Matters for Semaglutide Eligibility
Fasting Glucose & HbA1c Assess baseline glucose metabolism; identify undiagnosed or poorly controlled diabetes.
Kidney Function (eGFR, Creatinine) Semaglutide requires dose adjustment or caution if eGFR <15 mL/min/1.73m²; kidney disease may affect drug clearance.
Liver Function (AST, ALT, Bilirubin) Assess hepatic metabolism; significant elevation may require dose modification or clinical monitoring.
Lipid Panel & Triglycerides GLP-1 agonists may favorably shift lipids; baseline values help gauge response and cardiovascular risk.
Thyroid Function (TSH, Free T4) Establish baseline before treatment; monitor during therapy as GLP-1 may affect thyroid-stimulating hormone in some patients.

How Genetic Predispositions in GLP-1 Pathways May Inform Your Profile

Genetic variants in the GLP-1 receptor (GLP1R rs6923761), glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437), and metabolic regulators like FTO and MC4R influence how your body processes glucose, regulates appetite, and responds to GLP-1 therapy. These predispositions are not deterministic—they reflect inherited tendencies in peptide signaling pathways relevant to weight and metabolic health.

The PlexusDx Precision Peptide Genetic Test identifies your genetic variants in these key pathways. Understanding your profile may help provide context about your baseline metabolic tendencies and can support a more informed conversation with your healthcare provider about whether semaglutide aligns with your genetic and clinical picture. Genetics should always be interpreted alongside medical history, current labs, and provider assessment.

Who Should Not Take Semaglutide: Contraindications and Safety Considerations

Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Semaglutide carries a black-box warning for thyroid C-cell tumors in animal studies, though human thyroid cancer risk remains under ongoing surveillance. Patients with severe diabetic retinopathy, active pancreatitis, or history of severe allergic reaction to semaglutide should not use this medication.

Relative cautions include pregnancy (GLP-1 agonists are not recommended during pregnancy due to limited safety data), severe kidney disease, history of gastroparesis, or current use of medications that slow gastric emptying. Patients on insulin or other glucose-lowering agents require dose adjustments to prevent hypoglycemia when initiating semaglutide. Always discuss your complete health history, medications, and any surgeries with your provider before starting.

Building Your Eligibility Conversation with a Healthcare Provider

Bring your baseline lab results, current medication list, family health history, and details about any previous gastrointestinal or metabolic conditions to your provider appointment. If you've had significant weight fluctuations, multiple failed weight loss attempts, or recent lifestyle changes, document these as they provide valuable context for your provider's eligibility assessment and dose-planning strategy.

Consider requesting baseline biomarker testing if your provider hasn't ordered recent labs. Optional genetic testing (such as PlexusDx's Precision Peptide Genetic Test) can be discussed as an add-on to help both you and your provider understand your inherited predispositions in GLP-1 and metabolic pathways. This information, combined with clinical assessment, supports a more personalized treatment plan tailored to your unique health profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals your predispositions in key GLP-1 and metabolic pathways—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 variants. This genetic context may help provide background on your inherited tendencies in glucose regulation and appetite signaling, complementing your medical history and baseline labs.

Importantly, genetic predispositions do not predict exact medication response or guarantee weight loss outcomes. Your variants reflect inherited tendencies, not deterministic fate. They should always be interpreted with a qualified healthcare provider who integrates genetic insights, medical history, current biomarkers, and clinical judgment to assess your overall candidacy for semaglutide or other GLP-1 therapies.

By combining traditional medical eligibility assessment with optional biomarker and genetic insights, you and your provider can build a more complete picture of your metabolic profile. This integrated approach supports more informed shared decision-making about whether semaglutide aligns with your health goals and individual physiology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves